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Introduction. In cases of anatomic or functional single kidney with urothelial tumours of the upper urinary tract, the endoscopic
laser ablation has proven efficacious. Based on the knowledge that low-grade, low-stage upper tract transitional cell carcinomas
rarely progress to invasive lesions, indications for endoscopic laser ablation have expanded to include patients with bilateral
functioning kidneys and low-grade tumours. The question that remains to be answered is whether endoscopic laser ablation has
the ability to completely eradicate upper urinary tract tumours. Methods. We performed in 25 patients in a period of 11 years 288
ureteroscopies and, if needed, laser ablation of upper urinary tract tumours in imperative indication. Results. In 32% of the patients
the cancer remained even after several laser sessions. 64% of patients were tumour free after one ormore laser sessions but remained
clear only for the next 3 months. Only 1 patient was tumour free for a period of 68 months after 1 session of laser treatment. The
procedure had low complication rates. Conclusion. The laser technology and the introduction of small diameter semirigid and
flexible ureteroscopes made ablation of upper urinary tract tumours possible and safe. Nevertheless a complete resection of the
carcinomas is rarely possible.
1. Introduction
Upper urinary tract urothelial carcinomas (UTUCs) occur
with an incidence of 1-2/100.000 in Western countries and
comprise up to 5–10% of all urothelial carcinomas [1]. Radical
nephroureterectomy (RNU) with bladder cuff excision is
considered the gold standard treatment. However this pro-
cedure requires an intact contralateral kidney. In cases of a
solitary kidney, bilateral kidney involvement by tumour or
in cases of chronic renal insufficiency, organ preservation
is crucial, and kidney sparing approaches are indicated
(imperative indication).
The demonstrated lack of aggressiveness of low-grade
UTUCs together with the advent of improved ureteroreno-
scopes and advanced lasers technology has pushed the elec-
tive indications of endoscopic ablation of UTUC to include
patients with upper urinary tract urothelial tumours and
normal contralateral kidney function [1, 2] (nonimperative
or elective indication). The European Urology Guidelines
recommend the endoscopic treatment only for patients with
low-grade and low-stage urothelial tumours [1]. The success
rate of ureteroscopic therapy for grade 1 and grade 2 UTUCs
is similar to that of bladder lesions managed by transurethral
resection [3].
Endoscopic treatment of UTUCs can be performed
ureteroscopically or percutaneously.
The percutaneous approach is reserved for large tumours
and is associated with greater morbidity with transfusion
rates of 17% [4].
In the literature, 5-year survival rates of 100% for G1
tumours [5] versus 32–38% for G3 [6–8] have been reported.
5-year disease specific survival (DSS) has been reported to
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range between 81 and 100% for low-grade transitional cell
carcinomas (TCCs) versus 69–86% for high grade disease [9–
11] despite the inability of 32% to resect completely UTUCs
after multiple ureteroscopic procedures [12]. The recurrence
rate of UTUCs after endoscopic procedures was found to
range from 25.7% to 44.4% [13]. Tumour grade depended
recurrence rate was 40% for low-grade tumours versus 76%–
88% for high grade tumours [12, 14].
In our prospective study we managed 25 patients with
UTUCs ureteroscopically in imperative indication, and we
examine the ability to resect tumours completely after one or
more sessions.
2. Methods
25 patients, 13 men (52%) and 12 women (48%), under-
went endoscopic treatment for UTUCs ureteroscopically in
imperative indication. The average age of the patients was
71 ± 9 years. 10 patients had a single kidney (4 of them
not due to tumour and 6 after nephroureterectomy of the
contralateral kidney for UTUCs). 6 patients had comorbidity,
3 bilateral disease, and 6 borderline kidney insufficiency.
In all patients we performed ureterorenoscopy under gen-
eral anaesthesia every 3 months. Semirigid and flexible
ureteroscopes are used. Before each ureterorenoscopy, lavage
cytology specimens were taken, and a contrast medium was
given retrogradely.
Before laser treatment, tumour biopsies or biopsies from
the suspect area were conducted. Only when inspection,
retrograde imaging, lavage cytology, and biopsy were normal,
and the renal unit was considered tumour free.
Holmium laser device was used as the energy source
(Ho:YAG laser). For energy deliveringwe used a 365𝜇mfibre.
We worked with energy of 1.0−1.5 J and pulse between 6 and
8Hz. The surgery time amounted from 30 up to 150 minutes
(average 74.8 minutes) while the length of intermediate
inpatient stay was 4 days. After each ureterorenoscopy a DJ
stent was inserted for 2 weeks.
3. Results
14 (56%) patients had G1 urothelial tumour, 5 (20%) patients
had G1-2, 4 (16%) patients G2, and 2 patients (8%) a G3
urothelial tumour. In 14 (56%) patients tumour was solitary
and in 11 (44%) multifocal. Six (24%) patients had never
urinary bladder tumour before, 10 (40%) patients had urinary
bladder tumour in the history, 1 patient had synchronously
kidney pelvis and bladder tumour, and 7 (28%) patients
developed bladder tumour during the followup.
With a time range of 3 to 68 months (median 6 months),
8 (32%) patients did not manage to get tumour free even after
several laser sessions. Seven of them (68%) had multifocal
tumour and 1 patient a G3 tumour > 2.5 cm.
16 (64%) patients were tumour free after one or several
laser treatment sessions only for the next 3 months. At the
next ureteroscopy 3 months later, these patients showed a
recurrence and had to be treated. After 68 months and
Table 1
Number of patients 𝑛 = 25
Number of ureteroscopies 𝑛 = 288
Complications
3/25 Permanent ureter strictures (12%)
11/288 Bleeding required blood transfusion(3.8%)
1/25 Septicaemia with Klebsiella
1/25 Ureteral demolition
1 session laser treatment, only 1 patient was tumour free.
Patient had a solitary G1 tumour < 1.5 cm.
Thus, 24 of 25 patients (96%) relapsed during followup
of 68 months. In one patient we performed, after 2 years, a
nephroureterectomy because of local disease progression (CT
imaging).This patient had aG3 urothelial tumour of the renal
pelvis.
During followup of 68 months, we performed a total
of 288 ureteroscopies in 25 patients in a period of 11 years
(2000–2011). In 11 of 288 ureteroscopies (3.8%), there was a
bleeding required blood transfusion. In a patient, it came to
a septicaemia with Klebsiella. This patient had to be treated
in intensive care. In a patient with renal-pelvic tumour, it
came to ureteral demolition. Ureter was replaced by intestinal
segment. The followup was still possible through the bowel
segment. Three patients (12%) developed ureteral strictures
that were not due to tumour. In these patients, we perma-
nently left the DJ stent, and we changed it at each session
(Table 1).
During followup of 68 months (median 6 months), 1
patient with a G3 tumour died of pulmonarymetastases and 1
diabetic patient of the consequences of ischemic brain insult.
4. Discussion
The majority of the trials reported no progression in grade
and stage of low-grade upper tract urothelial tumours during
followup of average 32 months [2]. Disease specific mortality
for low-grade tumours was zero [2]. In the study ofMartinez-
Pineiro no deep tumour invasion in all patients with low-
grade lesions treated ureteroscopically was also found [15].
The situation is different in patients with high grade UTUCs.
While the 5-year survival rate for low grade tumours is 100%,
it is only 32% up to 38% for high grade UTUCs [9, 10, 15, 16].
Biopsies of UTUCs are not always able to determine the
right grade of the tumours. A study conducted by the Mayo
Clinic, in which the grade of the biopsies from UTUCs was
compared with the grade of the same tumours in kidney
preparation after ureteronephrectomy, showed that 96% of
G1 and 40% of G2 UTUCs in the biopsy were upgraded in
the nephrectomy preparation. In 25% of the cases biopsy was
unable to establish diagnosis [17]. Even if a G2 UTUC be
upgraded is simple a G3 UTUC. The recurrence rate of high
grade tumours is 76% up to 88% compared with 40% for low-
grade tumours [12, 14].
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Keeley found that the recurrence rate is also dependent
on the size of the primary tumour, and tumours > 1.5 cm had
a significantly higher rate of local recurrence [13]. In sum-
mary, disease recurrence is significantly influenced by initial
tumour characteristics: localisation, size, grade, multifocality,
and the concomitant presence or absence of bladder tumour.
Unfavorable are tumour size> 2 cm, location in kidney pelvis,
multifocality, and at least 3 previous resections of bladder
tumours [13, 18, 19]. Although another study has shown that
localisation of the tumour is less important for recurrence,
in this study local recurrence rate was 33% for renal-pelvic
tumours and 31% for ureteral tumours [20].
In spite of an increased recurrence rate, ureteroscopic
treatment of UUTT does not impair overall survival [21].
However, it must be said that the average age of patients in
all studies was about 70 years. In our study, we performed a
total of 288 ureteroscopies in 25 patients with UTUCs in a
period of 11 years. 32% of the patients were never tumour free
after multiple ureteroscopic laser procedures. This is exactly
the result of other studies [13, 15, 19]. After one or more
laser treatment sessions, 16 (64%) patients were at the next
control after 3 months of being tumour free. However in
the course, they showed a tumour recurrence. In only one
patient we reached a tumour free status for 68 months after
1 laser session. This patient had a solitary G1 ureteral tumour
< 1.5 cm. Complication rate of ureteroscopic management
of UTUCs is low (Table 1). Reported stricture rate in large
series has ranged from 5% to 14% [22]. Ureteral strictures
are not always a result of the medical act. Daneshmand et al.
found that 40% of patients with strictures after ureteroscopic
treatment had recurrent UTUCs [23]. In our study, 3 patients
(12%) developed strictures. Strictureswere not due to tumour.
5. Conclusions
The ureteroscopic treatment of UTUCs is technically pos-
sible and should be undertaken in patients with imperative
indication. Nevertheless a tumour free status can be achieved
only rarely. The complications rate is low. Progression rate is
very low for low-grade UTUCs. However, the extension of
indication on non imperative cases can be a problem, because
the overall recurrence rate is unclear and because the biopsy
cannot always indicate the right tumour grade.
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